Serena Williams, the 23-time Grand Slam tennis champion, has publicly shared her recent weight loss journey, revealing that she used GLP-1 medication to lose approximately 31 to 38 pounds over eight months following childbirth. Williams has positioned the medication as a tool complementing exercise, diet, and discipline rather than a shortcut. Her endorsement of GLP-1s, a class of weight-loss drugs, marks a notable departure from the typical profile of patients using these treatments. This revelation has sparked mixed reactions, with some critics expressing concern over the promotion of weight-loss drugs and the potential reinforcement of societal stigma around obesity. Public figures such as Jameela Jamil and Ulrika Jonsson have voiced criticism, highlighting debates about feminism and health messaging. Williams appeared publicly at the Tennis Hall of Fame, showcasing her changed physique. The discussion around her admission also coincides with broader media coverage on weight-loss injections, including reports of price surges and market dynamics in this pharmaceutical sector.